BiologicalDrug
Sotrovimab clinical trials
Also written VIR-7831 and GSK4182136.
- studies test it
- 17
- open now
- 2
- in phase 3
- 7
- first study started
- 2020
Keep track of what changes. Save the sotrovimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
17 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 7
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 17
Who runs them
Industry 8 · Other 9
Vir Biotechnology, Inc. (5) · GlaxoSmithKline (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Oxford (2) · Cambridge University Hospitals NHS Foundation Trust (1) · Sophia Koo, M.D. (1) · Eli Lilly and Company (1) · Fred Hutchinson Cancer Center (1)
Often tested with
Tested in the same studies.
Bamlanivimab (2) · Bebtelovimab (2) · Hydroxychloroquine (2) · Molnupiravir (2) · Nirmatrelvir and ritonavir drug combination (2) · Amubarvimab (1) · Romlusevimab (1) · Cilgavimab and tixagevimab drug combination (1)
Studies
Open first, then newest update. How each study uses sotrovimab is read from its arms, and is right about nine times in ten.
Testing it · 17
- Randomised Evaluation of COVID-19 TherapyRecruitingPhase 3University of OxfordNCT04381936Written as Sotrovimab
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Sotrovimab
- Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19CompletedPhase 4GlaxoSmithKlineNCT05305651Written as Sotrovimab
- PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -VCompletedPhase 2/3Cambridge University Hospitals NHS Foundation TrustNCT04870333Written as Sotrovimab
- Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB StudyTerminatedPhase 1Fred Hutchinson Cancer CenterNCT05135650Written as Sotrovimab
- Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)TerminatedPhase 1Vir Biotechnology, Inc.NCT05280717Written as sotrovimab
- A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised IndividualsCompletedPhase 2Sophia Koo, M.D.NCT05210101Written as Sotrovimab
- A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian ParticipantsCompletedPhase 1Vir Biotechnology, Inc.NCT04988152Written as sotrovimab
- Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.TerminatedPhase 3Vir Biotechnology, Inc.NCT04913675Written as sotrovimab
- Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19TerminatedPhase 2GlaxoSmithKlineNCT05124210Written as Sotrovimab
- VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780281Written as VIR-7831
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as VIR-7831
- UPMC OPTIMISE-C19 Trial, a COVID-19 StudyTerminatedPhase 4Erin McCrearyNCT04790786Written as Sotrovimab
- Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19CompletedPhase 2Vir Biotechnology, Inc.NCT04779879Written as Sotrovimab (Gen1)
- VIR-7831 for the Early Treatment of COVID-19 in OutpatientsCompletedPhase 2/3Vir Biotechnology, Inc.NCT04545060Written as VIR-7831 (sotrovimab)
- Non-inferiority Trial on Monoclonal Antibodies in COVID-19TerminatedPhase 3Azienda Ospedaliera Universitaria Integrata VeronaNCT05205759Written as Sotrovimab
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2Eli Lilly and CompanyNCT04634409Written as VIR-7831
As the comparator · 2 — what is tested is compared with sotrovimab
Codes
What other systems call sotrovimab · ClinicalTrials.gg INT001486
- MeSH (NLM) C000711967sotrovimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1MTK0BPN8VSOTROVIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2550731One source FDA
- Wikidata Q106943333SotrovimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C177059SotrovimabOne source FDA
- DrugBank DB16355One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711967 | sotrovimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1MTK0BPN8V | SOTROVIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2550731 | — | One source FDA |
| Wikidata | Q106943333 | Sotrovimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C177059 | Sotrovimab | One source FDA |
| DrugBank | DB16355 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.